To evaluate the anatomical and visual outcomes of patients who underwent pneumatic retinopexy by vitreoretinal fellows.
We included 198 eyes (198 patients) that underwent pneumatic retinopexy by vitreoretinal fellows at a single academic institution between November 2002 and June 2016. Main outcomes were single-operation success and final anatomical success in retinal reattachment, as well as visual acuity at 3 months and 6 months after treatment.
Single-operation success rate was 63.6% at 3 months and 59.5% at 6 months. Final anatomical reattachment was achieved in 92.9% (n = 184) and 96.6% (n = 143) at 3 months and 6 months, respectively. Logarithm of the minimum angle of resolution visual acuity improved from 0.72 ± 0.1 (∼20/100 Snellen) at baseline to 0.36 ± 0.06 (∼20/40 Snellen) at 6 months (P < 0.001). There was no statistical difference in anatomical success rates or visual outcomes between cases performed by first- or second-year fellows (P > 0.50). Single-operation success was associated only with size of detachment (P = 0.01). Visual outcome was associated with macula status at baseline (P = 0.032) and number of reoperations (P < 0.001).
Anatomical and visual outcomes of fellow-performed pneumatic retinopexy are comparable with those reported in the previous literature.
This retrospective study was conducted to evaluate outcomes of pneumatic retinopexy performed by vitreoretinal fellows in training. We showed that visual and anatomical outcomes of fellow-performed pneumatic retinopexy are comparable with those previously reported in the literature.
*Department of Ophthalmology & Vision Science, University of California, Davis, Sacramento, California; and
†Chicago Medical School, Rosalind Franklin University, Chicago, Illinois.
Reprint requests: Glenn Yiu, MD, PhD, Department of Ophthalmology and Vision Science, University of California, Davis Medical Center, 4860 Y Street, Suite 2400, Sacramento, CA 95817; e-mail: firstname.lastname@example.org
V. S. Vuong is supported by the National Center for Advancing Translational Sciences and NIH UL1TR000002. G. Yiu has research support from NIH K08 EY026101, E. Matilda Ziegler Foundation for the Blind, ARVO Foundation, Alcon Research Institute, and the California National Primate Research Center; and receives consultant fees from Allergan, Alimera, Carl Zeiss Meditec, and Iridex. S. S. Park has research support from Allergan and Roche/Novartis. A. Moshiri is supported by Research to Prevent Blindness and the International Retinal Research Foundation. L. S. Morse is on the Speakers' Bureau and Advisory Board of Genentech. No funding organizations had any role in the design or conduct of this research. The content is solely the responsibility of the authors and does not necessarily represent the official views of the funding agencies.
None of the authors has any conflicting interests to disclose.